On 29 January, Genetic Technologies Limited (NASDAQ: GENE) reported that up to 6 new breast diagnosis/treatment centres are expected to begin offering BREVAGenplus® to their at-risk patients in a systematic broad fashion in the January to March timeframe, with a growing number of additional new breast and imaging centre customers expected to follow later in calendar year 2015. On Friday shares of Genetic Technologies Limited (NASDAQ:GENE) closed at $3.95. Company’s sales growth for last 5 years was -16.50%.
Cambrex Corporation (NYSE:CBM) is pleased to announce that it has initiated the second significant expansion of its Charles City, Iowa facility in less than three years. Strong continued growth in demand for the Company’s active pharmaceutical ingredient (API) contract manufacturing capabilities is driving the need for more capacity. Cambrex Corporation. (NYSE:CBM) in last trading activity increased 27.54% to close at $30.01. Company weekly performance is 33.79% while its quarterly performance stands at 30.88%. Cambrex Corporation. (NYSE:CBM) is 22.74% away from its 52 week high.
On 5 February, Portola Pharmaceuticals (NASDAQ:PTLA) announced that the Independent Data Monitoring Committee (IDMC) recommended that the Phase 3 APEX (Acute Medically Ill VTE Prevention with Extended Duration Betrixaban) Study of betrixaban continue as planned without modification based on the successful completion of a pre-specified futility analysis On last trading day Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) increased 12.11% to close at $30.83. Its volatility for the week is 5.70% while volatility for the month is 5.80%. Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) monthly performance is 11.50%.
Coherus BioSciences, Inc. (NASDAQ:CHRS) announced that it will participate in a fireside chat at the 2015 Leerink Global Healthcare Conference on Wednesday, February 11 at 1:50 pm ET in New York City. Coherus Biosciences, Inc. (NASDAQ:CHRS) has 9.90% insider ownership while its institutional ownership stands at 36.40%. In last trading activity company’s stock closed at $28.66.
On 29 January, Vericel Corporation (NASDAQ:VCEL), announced the completion of patient enrollment in the company’s Phase 2b ixCELL-DCM clinical trial evaluating ixmyelocel-T for the treatment of advanced heart failure due to ischemic dilated cardiomyopathy (DCM). On last trading day Vericel Corporation (NASDAQ:VCEL) increased 7.41% to close at $3.48. Its volatility for the week is 4.16% while volatility for the month is 3.98%. VCEL’s EPS growth for past 5 years was 17.30%. Vericel Corporation (NASDAQ:VCEL) monthly performance is 16.39%.